Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AST 301

Next Previous
X
Search
Drug Profile

AST 301

Alternative Names: AST-301; EP-301; HER2-ICD vaccine; pNGVL3-hICD

Latest Information Update: 28 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiThany; University of Washington
  • Developer Aston Science; University of Washington
  • Class Antigens; Antineoplastics; Cancer vaccines; Immunotherapies; Vaccines
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Gastric cancer
  • No development reported Ovarian cancer

Most Recent Events

  • 31 May 2024 Aston Science terminates the phase-II Cornerstone001 trial in Breast cancer in Australia, Taiwan and USA due to difficulty in recruiting patients(NCT05163223)
  • 05 Apr 2024 Pharmacodynamics data from preclinical studies in Gastrica cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 04 Jul 2023 Phase-II Conerstone3 trial in Gastric cancer (In adults, In the elderly, Mid-stage disease, Second-line therapy or greater) in Taiwan (Parenteral) (NCT05771584)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top